StockData
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. (ANTX) stock

ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$4.95+0.72 (+17.02%)

Close on Nov 18, 2026Market cap $186.79MP/E –Yield –

AN2 Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

AN2 Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$38.81M. For fiscal 2025 it was -$38.11M. The highest annual figure on record is -$21.57M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$38.11M–
FY2024Dec 31, 2024-$56.79M–
FY2023Dec 31, 2023-$69.64M–
FY2022Dec 31, 2022-$42.26M–
FY2021Dec 31, 2021-$21.57M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.90M–
Q1 FY2026Mar 31, 2026-$10.55M–
Q4 FY2025Dec 31, 2025-$9.32M–
Q3 FY2025Sep 30, 2025-$10.04M–
Q2 FY2025Jun 30, 2025-$7.22M–
Q1 FY2025Mar 31, 2025-$11.54M–
Q4 FY2024Dec 31, 2024-$8.60M–
Q3 FY2024Sep 30, 2024-$14.01M–
Q2 FY2024Jun 30, 2024-$15.88M–
Q1 FY2024Mar 31, 2024-$18.30M–
Q4 FY2023Dec 31, 2023-$18.82M–
Q3 FY2023Sep 30, 2023-$18.18M–
Q2 FY2023Jun 30, 2023-$16.60M–
Q1 FY2023Mar 31, 2023-$16.04M–
Q4 FY2022Dec 31, 2022-$12.48M–
Q3 FY2022Sep 30, 2022-$11.77M–
Q2 FY2022Jun 30, 2022-$10.33M–
Q1 FY2022Mar 31, 2022-$7.68M–
Q4 FY2021Dec 31, 2021-$7.59M–
Q3 FY2021Sep 30, 2021-$6.93M–
Q2 FY2021Jun 30, 2021-$5.00M–
Q1 FY2021Mar 31, 2021-$2.05M–

More AN2 Therapeutics figures

See a number that looks wrong?